Stocktoria
Pyxis Oncology, Inc. PYXS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-10-08
Pyxis Oncology, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $13.9M | $16.1M | — | — | — |
| R&D expense | $73.7M | $58.7M | $49.6M | $86.1M | $51.1M |
| Operating income | -$84.4M | -$89.5M | -$82.2M | -$123.5M | -$69.7M |
| Income tax | $1.4M | -$2.2M | — | — | — |
| Net income | -$79.6M | -$77.3M | -$73.8M | -$120.7M | -$76.0M |
| EPS (diluted) | $-1.28 | $-1.32 | $-1.85 | $-3.65 | $-8.95 |
| Operating cash flow | -$63.5M | -$57.7M | -$70.7M | -$89.3M | -$35.3M |
| Free cash flow | -$63.5M | -$57.9M | -$77.4M | -$95.7M | -$35.9M |
| Cash & equivalents | $15.4M | $19.5M | $9.7M | $179.3M | $274.7M |
| Total assets | $91.5M | $157.2M | $173.7M | $211.4M | $280.0M |
| Total liabilities | $38.1M | $36.4M | $48.0M | $50.6M | $18.7M |
| Shareholders' equity | $53.4M | $120.8M | $125.7M | $160.8M | $261.3M |
Source: SEC EDGAR filings · CIK 0001782223 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.